PURPOSE: The present study was undertaken to test circulating autoantibody to ATP-binding cassette C3 (ABCC3) transporter in order to confirm whether anti-ABCC3 antibody could serve as a biomarker for early diagnosis of lung cancer. METHODS: This study recruited 275 patients (178 males and 97 females) with non-small cell lung cancer (either squamous carcinoma or adenocarcinoma) and 226 control subjects (134 males and 92 females) well matched in age and smoking history. Anti-ABCC3 IgA and IgG were determined using an enzyme-linked immunosorbent assay (ELISA) approach that was developed in house with the human leukocyte antigen class II (HLA-II) restricted antigens. RESULTS: Mann-Whitney U test showed that the IgG antibody level was significantly higher in female patients with adenocarcinoma than female controls (Z = -4.34, P < 0.001) and that the IgA antibody level was significantly higher in male patients with squamous carcinoma than male controls (Z = -3.12, P = 0.002). Pearson's Chi-square (χ(2)) test showed that female patients with adenocarcinoma had a significantly higher positive rate for IgG autoantibody than female controls (χ ( 2 ) = 8.73, P = 0.003). The ELISA sensitivity against a specificity of >95 % was 18.1 % for IgG assay in female patients and 18.0 % for IgA assay in male patients. The inter-assay deviation was 10.6 % for IgG assay and 14.5 % for IgA assay. CONCLUSIONS: Circulating autoantibodies to ABCC3 transporter may be a potential biomarker that can be added to a panel of existing biomarkers for early diagnosis and prognosis of lung cancer although the gender differences should be taken into account.
PURPOSE: The present study was undertaken to test circulating autoantibody to ATP-binding cassette C3 (ABCC3) transporter in order to confirm whether anti-ABCC3 antibody could serve as a biomarker for early diagnosis of lung cancer. METHODS: This study recruited 275 patients (178 males and 97 females) with non-small cell lung cancer (either squamous carcinoma or adenocarcinoma) and 226 control subjects (134 males and 92 females) well matched in age and smoking history. Anti-ABCC3 IgA and IgG were determined using an enzyme-linked immunosorbent assay (ELISA) approach that was developed in house with the human leukocyte antigen class II (HLA-II) restricted antigens. RESULTS: Mann-Whitney U test showed that the IgG antibody level was significantly higher in female patients with adenocarcinoma than female controls (Z = -4.34, P < 0.001) and that the IgA antibody level was significantly higher in male patients with squamous carcinoma than male controls (Z = -3.12, P = 0.002). Pearson's Chi-square (χ(2)) test showed that female patients with adenocarcinoma had a significantly higher positive rate for IgG autoantibody than female controls (χ ( 2 ) = 8.73, P = 0.003). The ELISA sensitivity against a specificity of >95 % was 18.1 % for IgG assay in female patients and 18.0 % for IgA assay in male patients. The inter-assay deviation was 10.6 % for IgG assay and 14.5 % for IgA assay. CONCLUSIONS: Circulating autoantibodies to ABCC3 transporter may be a potential biomarker that can be added to a panel of existing biomarkers for early diagnosis and prognosis of lung cancer although the gender differences should be taken into account.
Authors: Vivian Goodell; Lupe G Salazar; Nicole Urban; Charles W Drescher; Heidi Gray; Ron E Swensen; Martin W McIntosh; Mary L Disis Journal: J Clin Oncol Date: 2006-01-03 Impact factor: 44.544
Authors: Li Zhong; Sarah P Coe; Arnold J Stromberg; Nada H Khattar; James R Jett; Edward A Hirschowitz Journal: J Thorac Oncol Date: 2006-07 Impact factor: 15.609
Authors: A Murray; C J Chapman; G Healey; L J Peek; G Parsons; D Baldwin; A Barnes; H F Sewell; H A Fritsche; J F R Robertson Journal: Ann Oncol Date: 2010-02-02 Impact factor: 32.976
Authors: C Chapman; A Murray; J Chakrabarti; A Thorpe; C Woolston; U Sahin; A Barnes; J Robertson Journal: Ann Oncol Date: 2007-03-07 Impact factor: 32.976
Authors: P Boyle; C J Chapman; S Holdenrieder; A Murray; C Robertson; W C Wood; P Maddison; G Healey; G H Fairley; A C Barnes; J F R Robertson Journal: Ann Oncol Date: 2010-07-30 Impact factor: 32.976
Authors: Dominique de Costa; Ingrid Broodman; Wim Calame; Christoph Stingl; Lennard J M Dekker; René M Vernhout; Harry J de Koning; Henk C Hoogsteden; Peter A E Sillevis Smitt; Rob J van Klaveren; Theo M Luider; Martijn M Vanduijn Journal: PLoS One Date: 2014-05-01 Impact factor: 3.240
Authors: N E Annels; G R Simpson; M Denyer; S E McGrath; G Falgari; E Killick; R Eeles; J Stebbing; D Pchejetski; R Cutress; N Murray; A Michael; H Pandha Journal: Clin Exp Immunol Date: 2014-08 Impact factor: 4.330